Gary Lyman, Adjunct Professor of Medicine at Duke University School of Medicine, shared on LinkedIn:
“Circulating tumor DNA (ctDNA) evaluation, in which fragments of tumor DNA circulating in a patient’s bloodstream are extracted and analyzed, can be used to monitor cancer progression, detect residual cancer after treatment, and identify genetic changes within cancer cells that could affect treatment response.”
Title: Liquid Biopsies for Cancer – A Translational Science Review
Authors: Jessica Mezzanotte-Sharpe, Katrina Piemonte, Ben H. Park.
Read The Full Article.